Japan Grants Orphan Drug Designation to Givinostat for Duchenne Muscular Dystrophy
核心洞察
Japan's Ministry of Health, Labour and Welfare granted orphan drug designation to givinostat, an investigational oral HDAC inhibitor for Duchenne muscular dystrophy (搜索).
JCR Pharmaceuticals (搜索) licensed givinostat from Italfarmaco (搜索) in December 2025 and plans to file a Japanese marketing authorization application by the end of 2026.
Givinostat, marketed as Duvyzat in the US, EU and UK for patients aged 6 years and older, is not yet approved in Japan.
Japan's Ministry of Health, Labour and Welfare has granted orphan drug designation to givinostat, an investigational oral therapy for Duchenne muscular dystrophy (搜索) (DMD), JCR Pharmaceuticals (搜索) announced on September 28, 2026. The designation covers a disease that affects an estimated 3,500 patients in Japan and for which givinostat is not yet approved in the country.
Givinostat is an orally administered histone deacetylase (搜索) (HDAC) inhibitor developed by Italfarmaco (搜索) S.p.A. and marketed as Duvyzat in the United States, the European Union and the United Kingdom, where it is prescribed to patients aged 6 years and older with DMD in accordance with local prescribing information. Alongside the orphan designation, the product has been granted Priority Examination status in Japan.
Licensing and Regulatory Path in Japan
JCR entered an exclusive license agreement with Italfarmaco (搜索) in December 2025 for the development and commercialization of givinostat in Japan. The company is advancing development toward marketing approval and plans to submit a marketing authorization application in Japan by the end of 2026.
"The designation of givinostat as both an orphan drug and a product eligible for Priority Examination represents an important milestone toward its commercialization in Japan," said Hiroyuki Sonoda, Ph.D., President and Chief Scientific Officer of JCR Pharmaceuticals (搜索). "We remain committed to bringing this new treatment option to patients with DMD in Japan as quickly as possible, addressing the significant unmet medical needs of the DMD community."
Under Japan's orphan drug designation system, the Ministry of Health, Labour and Welfare takes special measures to support and promote research into drugs for rare diseases. Products may qualify if they target a condition with fewer than 50,000 patients in Japan, or if their intended use is for a designated intractable disease. They must also address serious or difficult-to-treat diseases with high unmet medical need, such as where no approved medicinal product exists or where higher efficacy or improved safety is expected relative to an approved product. Applicants must demonstrate sufficient resources and development plans for the product in Japan.
Mechanism Independent of Dystrophin Mutation
DMD is a rare, progressive neuromuscular disorder caused by mutations in the dystrophin (搜索) gene. These mutations prevent production of functional dystrophin, causing the dystrophin-associated protein complex (DAPC) to break down. Muscle fibres become more vulnerable to damage, and histone deacetylase (搜索) levels rise in muscle cells, blocking activation of genes needed for muscle maintenance and repair. The result is ongoing fibre damage, chronic inflammation and poor regeneration, with muscle cells eventually dying and being replaced by scar tissue and fat.
Givinostat regulates the excessive HDAC activity characteristic of DMD muscle, helping restore expression of key genes and biological processes essential for muscle maintenance and repair. Its mechanism of action is independent of the specific dystrophin (搜索) gene mutation causing the disease. The compound was discovered through Italfarmaco (搜索)'s research and development efforts in collaboration with Telethon and Duchenne Parent Project (Italy).
Disease Course and Patient Burden
DMD primarily affects males, with symptoms typically appearing between the ages of two and five years. As the condition progresses, muscle weakness worsens, leading to difficulty walking and eventually loss of ambulation. The heart and respiratory muscles are later affected, and these complications are the leading causes of premature death. DMD is one of the most severe and common forms of childhood muscular dystrophy, with a global birth incidence of approximately 1 in 5,050 boys.
Italfarmaco (搜索), founded in 1938 in Milan, Italy, is a private global pharmaceutical company with operations in more than 90 countries through directly controlled or affiliated companies. Its rare disease unit includes programs in Duchenne muscular dystrophy (搜索), Becker muscular dystrophy (搜索), amyotrophic lateral sclerosis (搜索) and polycythemia vera (搜索).
JCR Pharmaceuticals (搜索) is a specialty pharmaceutical company with a 50-year legacy in Japan and an expanding footprint in the United States, Europe and Latin America. Its approved products in Japan include therapies for growth disorder, MPS II (Hunter syndrome (搜索)), Fabry disease (搜索), acute graft-versus-host disease and renal anemia. Its investigational pipeline targets rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, and MPS IIIA and B (Sanfilippo syndrome (搜索) type A and B).